Profile data is unavailable for this security.
About the company
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
- Revenue in USD (TTM)4.81bn
- Net income in USD1.19bn
- Incorporated1991
- Employees2.62k
- LocationIncyte Corp1801 Augustine Cut-OffWILMINGTON 19803United StatesUSA
- Phone+1 (302) 636-5400
- Fax+1 (302) 636-5454
- Websitehttps://www.incyte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | 3.09bn | 520.42m | 10.98bn | 3.04k | 21.42 | 1.81 | 18.20 | 3.55 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Avidity Biosciences Inc | 20.87m | -549.79m | 11.27bn | 391.00 | -- | 5.67 | -- | 539.97 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Elanco Animal Health Inc | 4.59bn | 36.00m | 12.08bn | 9.00k | 339.43 | 1.79 | 17.11 | 2.63 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| BridgeBio Pharma Inc | 353.78m | -797.12m | 12.28bn | 725.00 | -- | -- | -- | 34.71 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
| Neurocrine Biosciences Inc | 2.68bn | 428.00m | 13.75bn | 1.80k | 32.93 | 4.58 | 30.05 | 5.13 | 4.19 | 4.19 | 26.25 | 30.13 | 0.6878 | 0.7611 | 4.44 | 1,490,389.00 | 10.97 | 10.41 | 12.71 | 12.71 | 98.37 | 98.47 | 15.95 | 15.71 | 3.27 | -- | 0.00 | -- | 24.81 | 24.48 | 36.68 | 55.94 | 20.97 | -- |
| Roivant Sciences Ltd | 20.33m | -700.99m | 14.70bn | 750.00 | -- | 3.34 | -- | 723.24 | -1.00 | -0.5524 | 0.0291 | 6.32 | 0.0036 | -- | -- | 27,105.33 | -16.00 | 5.89 | -18.57 | 6.98 | 96.41 | 90.39 | -4,433.42 | 639.97 | -- | -- | 0.00 | 0.00 | -11.19 | -15.56 | -111.69 | -- | -1.32 | -- |
| Moderna Inc | 2.23bn | -3.12bn | 15.97bn | 5.80k | -- | 1.71 | -- | 7.15 | -8.05 | -8.05 | 5.76 | 23.86 | 0.1598 | 2.19 | 1.71 | 384,827.60 | -22.31 | 13.72 | -25.91 | 18.76 | 63.49 | 76.34 | -139.61 | 23.74 | 3.73 | -- | 0.0061 | 0.00 | -52.75 | 121.86 | 24.46 | -- | 101.61 | -- |
| Viatris Inc | 14.12bn | -3.69bn | 16.52bn | 32.00k | -- | 1.09 | -- | 1.17 | -3.10 | -3.10 | 11.96 | 13.13 | 0.3417 | 2.09 | 4.90 | 441,387.50 | -8.93 | -0.1756 | -10.89 | -0.2096 | 39.36 | 40.66 | -26.13 | -0.5768 | 0.793 | 2.79 | 0.4868 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
| Incyte Corp | 4.81bn | 1.19bn | 20.17bn | 2.62k | 17.37 | 4.33 | 15.75 | 4.19 | 5.91 | 5.91 | 23.91 | 23.71 | 0.8487 | 4.09 | 5.82 | 1,839,169.00 | 20.96 | 6.35 | 27.96 | 7.89 | 93.47 | 94.43 | 24.69 | 9.56 | 3.13 | -- | 0.0076 | 0.00 | 14.76 | 14.46 | -94.54 | -40.76 | 2.02 | -- |
| United Therapeutics Corp | 3.13bn | 1.27bn | 20.62bn | 1.31k | 18.13 | 3.12 | 15.23 | 6.59 | 26.41 | 26.41 | 64.94 | 153.61 | 0.4323 | 2.21 | 9.78 | 2,397,242.00 | 17.57 | 13.61 | 19.48 | 14.84 | 88.59 | 90.79 | 40.65 | 37.81 | 6.07 | -- | 0.00 | 0.00 | 23.63 | 14.71 | 21.35 | -- | 24.11 | -- |
| Royalty Pharma plc | 2.35bn | 764.96m | 25.46bn | 99.00 | 25.22 | 3.98 | 29.20 | 10.83 | 1.75 | 1.75 | 4.11 | 11.08 | 0.1257 | -- | 87.35 | 23,735,800.00 | 6.97 | 7.56 | 8.95 | 10.21 | -- | -- | 55.43 | 55.06 | -- | 6.91 | 0.4818 | 46.51 | -3.86 | 4.52 | -24.31 | -18.22 | 7.80 | -- |
| Biogen Inc | 10.07bn | 1.61bn | 27.19bn | 7.61k | 16.90 | 1.49 | 11.46 | 2.70 | 10.97 | 10.97 | 68.67 | 124.11 | 0.35 | 1.07 | 5.25 | 1,323,590.00 | 5.59 | 9.02 | 6.59 | 10.69 | 75.24 | 81.00 | 15.98 | 21.25 | 2.04 | 5.07 | 0.2566 | 0.00 | -1.62 | -7.62 | 40.57 | -22.63 | -11.68 | -- |
Data as of Feb 06 2026. Currency figures normalised to Incyte Corp's reporting currency: US Dollar USD
55.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2025 | 31.01m | 15.79% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 18.26m | 9.30% |
| Dodge & Coxas of 30 Sep 2025 | 13.93m | 7.10% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 11.53m | 5.87% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 9.68m | 4.93% |
| AQR Capital Management LLCas of 30 Sep 2025 | 7.92m | 4.04% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 4.53m | 2.31% |
| Geode Capital Management LLCas of 30 Sep 2025 | 4.49m | 2.29% |
| LSV Asset Managementas of 30 Sep 2025 | 3.99m | 2.03% |
| Arrowstreet Capital LPas of 30 Sep 2025 | 3.10m | 1.58% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
